An overview of the pharmacology of rocuronium bromide in experimental animals.
In various animal species anaesthetized with a-chloralose (cats and pigs) or pentobarbitone (Beagle dogs and Rhesus monkeys), rocuronium has been shown to be a readily reversible, non-depolarizing neuromuscular blocking agent with a similar duration of action as vecuronium but a 6-10 fold lower potency. The outstanding features of its action is rapidity of onset. It is not expected to have any marked cardiovascular or autonomic side-effects when used in the neuromuscular blocking dose range. There is no evidence of any selective pre-junctional effect and there is no clinically relevant inhibition of acetycholinesterase. Screening in rats has not demonstrated any oestrogenic, androgenic, anabolic, glucocorticoid-like or gonad-inhibiting properties, although there was a slight increase in pituitary weight in male rats.
Marshall
R J
RJ
Scientific Development Group, Organon Laboratories Limited, Newhouse, Scotland, UK.
Muir
A W
AW
Sleigh
T
T
Savage
D S
DS
D000110:Acetylcholinesterase / Q000378:metabolism; D000732:Androstanols / Q000494:pharmacology*; D000758:Anesthesia; D000818:Animals; D002319:Cardiovascular System / Q000187:drug effects; D002415:Cats; D004285:Dogs; D005260:Female; D006801:Humans; D008253:Macaca mulatta; D008297:Male; D009469:Neuromuscular Junction / Q000187:drug effects / Q000502:physiology; D003473:Neuromuscular Nondepolarizing Agents / Q000494:pharmacology*; D051381:Rats; D000077123:Rocuronium; D013552:Swine; D009435:Synaptic Transmission / Q000187:drug effects
D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D000110:Acetylcholinesterase; D000077123:Rocuronium